[go: up one dir, main page]

WO2003107008A3 - POLYMORPHISME DIAGNOSTIQUE DE LA 11ss-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE UTILE POUR IDENTIFIER LE RISQUE DE DÉVELOPPEMENT DE LA MALADIE D'ALZHEIMER - Google Patents

POLYMORPHISME DIAGNOSTIQUE DE LA 11ss-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE UTILE POUR IDENTIFIER LE RISQUE DE DÉVELOPPEMENT DE LA MALADIE D'ALZHEIMER Download PDF

Info

Publication number
WO2003107008A3
WO2003107008A3 PCT/EP2003/006315 EP0306315W WO03107008A3 WO 2003107008 A3 WO2003107008 A3 WO 2003107008A3 EP 0306315 W EP0306315 W EP 0306315W WO 03107008 A3 WO03107008 A3 WO 03107008A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
development
alzheimer
risk
identifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/006315
Other languages
English (en)
Other versions
WO2003107008A2 (fr
Inventor
Quervain Dominique De
Andreas Papassotiropoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Priority to AU2003246438A priority Critical patent/AU2003246438A1/en
Priority to EP03759962A priority patent/EP1514119A2/fr
Publication of WO2003107008A2 publication Critical patent/WO2003107008A2/fr
Publication of WO2003107008A3 publication Critical patent/WO2003107008A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention est fondée sur l'association surprenante d'un polymorphisme dans le gène codant pour HSD11B1 avec un risque génétique accru de développement d'une maladie neurodégénérative, en particulier la maladie d'Alzheimer, et concerne une méthode permettant de diagnostiquer et de pronostiquer une telle maladie, ou de déterminer la propension ou la prédisposition d'un sujet à développer une telle maladie. Ladite méthode consiste à détecter la présence ou l'absence d'un polymorphisme de nucléotide simple dans le gène codant pour HSD11B1.
PCT/EP2003/006315 2002-06-17 2003-06-16 POLYMORPHISME DIAGNOSTIQUE DE LA 11ss-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE UTILE POUR IDENTIFIER LE RISQUE DE DÉVELOPPEMENT DE LA MALADIE D'ALZHEIMER Ceased WO2003107008A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003246438A AU2003246438A1 (en) 2002-06-17 2003-06-16 DIAGNOSTIC POLYMORPHISM OF 11ss-HYDROXYSTEROID DEHYDROGENASE USEFUL FOR IDENTIFYING RISK OF DEVELOPING ALZHEIMER'S DISEASE
EP03759962A EP1514119A2 (fr) 2002-06-17 2003-06-16 Polymorphisme diagnostique de la 11 -hydroxyst ro de d shydrog nase utile pour identifier le risque de d veloppement de la maladie d'alzheimer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02013239.5 2002-06-17
EP02013239 2002-06-17

Publications (2)

Publication Number Publication Date
WO2003107008A2 WO2003107008A2 (fr) 2003-12-24
WO2003107008A3 true WO2003107008A3 (fr) 2004-03-25

Family

ID=29724390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/006315 Ceased WO2003107008A2 (fr) 2002-06-17 2003-06-16 POLYMORPHISME DIAGNOSTIQUE DE LA 11ss-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE UTILE POUR IDENTIFIER LE RISQUE DE DÉVELOPPEMENT DE LA MALADIE D'ALZHEIMER

Country Status (3)

Country Link
EP (1) EP1514119A2 (fr)
AU (1) AU2003246438A1 (fr)
WO (1) WO2003107008A2 (fr)

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 409, 15 February 2001 (2001-02-15), pages 928 - 933, XP002193850, ISSN: 0028-0836 *
DATABASE SNP-DATABASE OF NCBI [online] 29 January 2001 (2001-01-29), XP002220033, retrieved from SNP-DATABASE OF NCBI Database accession no. rs846911 *
DATABASE SNP-DATABASE OF NCBI [online] 9 February 2000 (2000-02-09), XP002263453, retrieved from SNP-DATABASE OF NCBI Database accession no. rs860150 *
DE KLOET E RONALD ET AL: "Brain corticosteroid receptor balance in health and disease.", ENDOCRINE REVIEWS, vol. 19, no. 3, June 1998 (1998-06-01), pages 269 - 301, XP002220013, ISSN: 0163-769X *
KNIGHT J C ET AL: "A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria [see comments]", NATURE GENETICS, NATURE AMERICA, NEW YORK, US, vol. 22, no. 2, June 1999 (1999-06-01), pages 145 - 150, XP002139041, ISSN: 1061-4036 *
KOTELEVTSEV YURI ET AL: "11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 94, no. 26, 23 December 1997 (1997-12-23), Dec. 23, 1997, pages 14924 - 14929, XP002220014, ISSN: 0027-8424 *
RAJAN VIDYA ET AL: "11-beta-Hydroxysteroid dehydrogenase in cultured hippocampal cells reactivates inert 11-dehydrocorticosterone, potentiating neurotoxicity", JOURNAL OF NEUROSCIENCE, vol. 16, no. 1, 1996, pages 65 - 70, XP002263452, ISSN: 0270-6474 *
SECKL J R ET AL: "Enzymes, receptors and glucocorticoid action on the brain.", JOURNAL OF ENDOCRINOLOGY, vol. 156, no. SUPPL., March 1998 (1998-03-01), 17th Joint Meeting of the British Endocrine Societies;Edinburgh, Scotland, UK; March 23-25, 1998, pages S24, XP008009951, ISSN: 0022-0795 *
SEIGEL A T ET AL: "Homology modelling of the 11beta-hydroxysteroid dehydrogenase isozymes.", BRITISH JOURNAL OF PHARMACOLOGY, vol. 134, no. Proceedings Supplement, November 2001 (2001-11-01), Meeting of the British Pharmacological Society;Dublin, Ireland; July 03-05, 2001, pages 113P, XP001051165, ISSN: 0007-1188 *
VESELL E S: "INTRODUCTION", PHARMACOLOGY, XX, XX, vol. 61, no. 3, 2000, pages 118 - 123, XP008001593, ISSN: 0031-7012 *
WU GARY D ET AL: "Oct-1 and CCAAT/enhancer-binding protein (C/EBP) bind to overlapping elements within the interleukin-8 promoter. The role of Oct-1 as a transcriptional repressor.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 4, 1997, pages 2396 - 2403, XP002222664, ISSN: 0021-9258 *
YAU JOYCE L W ET AL: "Lack of tissue glucocorticoid reactivation in 11beta-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 8, 10 April 2001 (2001-04-10), April 10, 2001, pages 4716 - 4721, XP002220012, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1514119A2 (fr) 2005-03-16
WO2003107008A2 (fr) 2003-12-24
AU2003246438A1 (en) 2003-12-31
AU2003246438A8 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
Bonnefond et al. Whole-exome sequencing and high throughput genotyping identified KCNJ11 as the thirteenth MODY gene
Rost et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
EP1542009B1 (fr) Procede de detection d'acide nucleique par utilisation de microreseaux d'adn, et appareil de detection d'acide nucleique
Borecki et al. Associations of candidate loci angiotensinogen and angiotensin-converting enzyme with severe hypertension: The NHLBI Family Heart Study
Quenez et al. Detection of copy-number variations from NGS data using read depth information: a diagnostic performance evaluation
Tatsumoto et al. Direct estimation of de novo mutation rates in a chimpanzee parent-offspring trio by ultra-deep whole genome sequencing
DK1715063T3 (da) Hydridiseringsbeacon og fremgangsmåde til hurtig sekvensdetektion og distinktion
JPWO2008130008A1 (ja) 緑内障発症リスクの判定方法
White et al. A roadmap for high‐throughput sequencing studies of wild animal populations using noninvasive samples and hybridization capture
MA32619B1 (fr) Procede d'identification de facteurs de risque de maladie
Gao et al. Whole exome sequencing identifies a novel DFNA9 mutation, C162Y
Song et al. Molecular diagnosis of autosomal dominant polycystic kidney disease
EP1531180A4 (fr) Methode de diagnostic du risque d'infarctus du myocarde
Kim et al. A double‐screening method to identify reliable candidate non‐synonymous SNPs from chicken EST data
WO2004058051A3 (fr) Genes regules par l'androgene et utilisations dans le diagnostic, le pronostic et le traitement de troubles neoplasiques de la prostate
WO2003107008A3 (fr) POLYMORPHISME DIAGNOSTIQUE DE LA 11ss-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE UTILE POUR IDENTIFIER LE RISQUE DE DÉVELOPPEMENT DE LA MALADIE D'ALZHEIMER
US20170067110A1 (en) Detection method for genetic disease
Bigio et al. Detection of homozygous and hemizygous complete or partial exon deletions by whole-exome sequencing
Santos et al. Huntington disease‐like 2: the first patient with apparent European ancestry
Nghiem et al. Association of the STAT4, CDKN1A, and IRF5 variants with risk of lupus nephritis and renal biopsy classification in patients in Vietnam
WO2003060160A3 (fr) Verification des origines alimentaires fondees sur la reconnaissance du motif d'acide nucleique
Wu et al. Molecular analyses of GCH‐1, TH and parkin genes in Chinese dopa‐responsive dystonia families
Goncalves da Silva et al. SNP discovery in nonmodel organisms: strand bias and base‐substitution errors reduce conversion rates
KR102570462B1 (ko) MYO15B 유전자의 rs820148 부위를 이용한 여성의 우울증 위험도 예측용 바이오마커, 상기 바이오마커를 이용한 여성의 우울증 위험도 진단에 대한 정보제공방법 및 진단키트
Curnow et al. The L10F mutation of angiotensinogen is rare in pre-eclampsia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003759962

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003759962

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP